Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119831
Chunk: 49

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 49
---
,
subject us to civil and criminal investigations and penalties, and generally materially and adversely impact our business and financial condition.

If, in the future, we identify material weaknesses in our internal controls over financial reporting or fail to meet the demands that will be
placed upon us as a public company, including the requirements of the Sarbanes-Oxley Act, we may be unable to accurately report our financial results or report them within the timeframes required by law or stock exchange regulations. Failure to
comply with Section 404 of the Sarbanes-Oxley Act could also potentially subject us to sanctions or investigations by the SEC or other regulatory authorities. If additional material weaknesses exist or are discovered in the future, and we are
unable to remediate any such material weakness, our business, financial condition and results of operations could suffer.

31

Risks Related to our Commercial Operations and Product Development We obtain, or historically have obtained, our commercial supply of certain of our products, the clinical supply of our product candidates and certain of the raw materials used in our product candidates from sole or single source suppliers and manufacturers. In the event of a loss of one of these suppliers or manufacturers, or a failure by any such supplier or manufacturer to comply with FDA regulations, we may not be able to find an alternative source on commercially reasonable terms, or at all. We rely on a number of sole or single source suppliers and manufacturers, including:

| • |     | the manufacturer and supplier for the commercial supply of ZTlido, ELYXYB and GLOPERBA; |

| • |     | the manufacturer and supplier for the clinical supply of SP-103; |

| • |     | the manufacturer and supplier for the clinical supply of SP-104; |

| • |     | the supplier of sodium hyaluronate, one of the excipients for SEMDEXA; and |

| • |     | the manufacturer for the clinical supply of SEMDEXA. |

Under the Product Development Agreement and the Commercial Supply Agreement, we license the rights to ZTlido from, and rely exclusively on, Oishi and Itochu for the manufacturing and supply of ZTlido and SP-103.Oishi and Itochu have the right to terminate the Product Development Agreement and the Commercial Supply Agreement under certain circumstances, including, among other things: (1) if we are in material breach of the agreement and the breach is not curable or if the breach is curable and we fail to cure such material breach within